BAT Expresses Disappointment At FDA Marketing Denial Order For Vuse Alto Menthol And Mixed Berry And Will Immediately Seek A Stay Of Enforcement
Portfolio Pulse from Benzinga Newsdesk
British American Tobacco (BAT) has expressed disappointment at the FDA's Marketing Denial Orders (MDOs) for Vuse Alto's Menthol and Mixed Berry products. The company plans to challenge the decision and seek a stay of enforcement. The FDA's decision was based on the absence of long-term consumer switching data for these products. BAT argues that this decision contradicts proven science and the FDA's goal of reducing the health effects of tobacco use. The company also expressed concern about the FDA allowing the proliferation of youth-appealing vapor products.
October 12, 2023 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BAT's plans to challenge the FDA's decision could lead to legal costs and potential delays in product launches. The company's reputation could also be affected if it is perceived as not prioritizing public health.
The FDA's decision to deny marketing orders for BAT's Vuse Alto products could negatively impact the company's revenues and profitability. The company's decision to challenge this could lead to legal costs and potential delays in product launches. Additionally, if BAT is perceived as not prioritizing public health, this could harm its reputation and potentially affect its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100